Keros Therapeutics KROS 深 滬
已收盤 08-08 16:00:00 美东时间
13.73
+0.370
+2.77%
華盛通- 最 高13.75
- 今 開13.32
- 成交量 71.68万股
- 最 低 13.1944
- 昨 收 13.36
- 總市值 5.58亿
- 52周最高 72.37
- 市盈率 靜 --
- 換手率 1.76%
- 52周最低 9.12
- 委 比 -60.73%
- 總股本 4061.54万
- 歷史最高 88.80
- 量 比 1.77
- 振 幅 4.16%
- 歷史最低 9.12
- 每 手 1
- 風險率 11.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Keros Therapeutics Announces Strategic Realignment To Reallocate Resources Towards Development Of Its Key Clinical Program, KER-065; Discontinues Development of Cibotercept (KER-012)
Company Discontinuing Development of Cibotercept (KER-012)Announces Board and Leadership Changes Designed to Support Streamlined Operational Structureand Strategic RealignmentLEXINGTON, Mass., Aug. 06, 2025 (GLOBE
08-07 04:59
Keros Therapeutics Q2 EPS $(0.76) Beats $(1.11) Estimate, Sales $18.168M Beat $2.767M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.11) by 31.78 percent. This is a 39.2 percent increase over losses of $(1.25) per share from
08-07 04:45
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Keros Therapeutics has discontinued development of cibotercept (KER-012) and realigned its operations to focus on its lead clinical program, KER-065, for Duchenne muscular dystrophy. The company has also made leadership changes, including Jasbir S. Seehra becoming President, Jean-Jacques Bienaimé as Board Chair, and Christopher Rovaldi stepping down as COO. These changes aim to support the streamlined focus on advancing KER-065.
08-06 20:15
Kratos, Champion Tire & Wheel Launch Industry-First Automated Truck Platoon to Support NASCAR Brickyard 400 Logistics
Kratos Defense & Security Solutions and Champion Tire & Wheel successfully deployed the first automated truck platoon to support the Brickyard 400, using driverless technology for motorsports logistics. Two tractor-trailers, equipped with advanced V2V communications and automation, transported tires and equipment between Ohio and Indiana, demonstrating how this technology can enhance commercial logistics efficiency and scalability. The deployment...
07-29 12:00
Keros Therapeutics Announces First Patient Dosed In Phase 3 RENEW Clinical Trial Of Elritercept In Adults With Transfusion-Dependent Anemia With Very Low, Low, Or Intermediate Risk MDS
Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked
07-17 20:16
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Keros Therapeutics has initiated dosing of the first patient in its Phase 3 RENEW trial for elritercept in adults with transfusion-dependent anemia linked to MDS, triggering a $10 million milestone payment from Takeda under their global license agreement. Elritercept, a TGF-β receptor engineered ligand trap, aims to reduce red blood cell transfusions in these patients.
07-17 12:00
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns.
06-11 02:37
Keros Therapeutics Board Determines To Initiate Process To Return $375M Of Excess Capital To Stockholders
Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders
06-09 18:56
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Keros Therapeutics has concluded its strategic alternatives review and plans to return $375 million of excess capital to shareholders while continuing development of its lead product candidate, KER-065, targeting neuromuscular diseases, particularly Duchenne muscular dystrophy. The Board emphasized enhancing shareholder value and confidence in KER-065's potential to provide meaningful benefits. This decision followed a comprehensive review of opt...
06-09 10:55
